


- 2 -

The following is a complete listing of all claims in the application, with an indication of the status of each:

Listing of claims:

1. (Previously presented) A compound of the general formula



where

m is an integer from 0 to 5;

n is an integer from 0 to 5;

R is C₁ to C₇ alkyl, cycloalkyl, phenyl, hydroxy, alkyl hydroxy, substituted phenyl, or CH₂X¹, where X¹ = H, Cl, Br, I or F;


R₁ is H, C₁ to C₇ alkyl, phenyl, or substituted phenyl;

R₂, R₃, R₄ and R₅ are H or C₁ to C₇ alkyl, and R₁, R₂, R₃, R₄ and R₅ may be the same or different; and


X is C H₂ or a saturated or unsaturated C₂ carbon chain.

-3-


2. (Previously presented) A compound of formula



3. (Previously presented) A compound of formula




4. (Previously presented) A compound of formula




- 4 -

5. (Previously presented) A compound of formula




6. (Previously presented) A compound of formula



7. (Currently amended) A method of treatment of a condition or disorders related to cannabinoid-regulated systems in a patient in need thereof, wherein if said compound is an agonist of a CB1 receptor then said condition is selected from the group consisting of acute pain; chronic pain; inflammation; loss of appetite; convulsions; spasticity associated with multiple sclerosis; convulsions; epilepsy; and nausea and vomiting; and wherein if said compound is a silent antagonist of a CB1 receptor then said condition is selected from the group consisting of obesity; impaired cognition; and alcohol, tobacco, cocaine or marijuana dependence; comprising the step of

- 5 -

administering to said patient a quantity of a compound of formula



where

m is an integer from 0 to 5;

n is an integer from 0 to 5;

R is C₁ to C₆ alkyl, cycloalkyl, phenyl, hydroxy, alkyl hydroxy, substituted phenyl, or CH₂X¹, where X¹ = H, Cl, Br, I or F;

R₁ is I, C₁ to C₆ alkyl, phenyl, or substituted phenyl;

R₂, R₃, R₄ and R₅ are H or C₁ to C₆ alkyl, and R₁, R₂, R₃, R₄ and R₅ may be the same or different; and


X is C₁H₂ or a saturated or unsaturated C₂ carbon chain,

in a quantity sufficient to ameliorate symptoms of said condition or disorder.

8-9. (Cancel)

10. (Currently amended) A method for treating pain in a patient comprising administering to said patient an effective dose of an agonist of a CB1 cannabinoid receptor wherein said agonist includes a sulfonamide moiety, and wherein said agonist has the chemical formula


- 6 -

wherem is a integer from 0 to 5;n is an integer from 0 to 5;R is C₁ to C₇, alkyl, cycloalkyl, phenyl, hydroxy, alkyl hydroxy, substituted phenyl, or CH₂X¹, where X¹ = H, Cl, Br, I or F;R₁ is C₁ to C₇, alkyl, phenyl, or substituted phenyl;R₂, R₃, R₄ and R₅ are H or C₁ to C₇, alkyl, and R₁, R₂, R₃, R₄ and R₅ may be the same or different; andX is C H₂, or a saturated or unsaturated C₂ carbon chain, with the proviso that if R is CH₂, then X must be CH₂, or a saturated C₂ carbon chain.

1


11. (Cancel)

12. (Previous y presented) The method of claim 10 wherein said agonist is selected from the group consisting of




-7-

and



13. (Currently amended) A method for treating nausea in a patient comprising administering to said patient an effective dose of an agonist of a CB1 cannabinoid receptor wherein said agonist includes a sulfonamide moiety, and wherein said agonist has the chemical formula



where

m is a integer from 0 to 5:

n is an integer from 0 to 5;

- 8 -

R is C₁ to C₇ alkyl, cycloalkyl, phenyl, hydroxy, alkyl hydroxy, substituted phenyl, or CH₂X¹, where X¹ = H, Cl, Br, I or F;


R₁ is F, C₁ to C₇ alkyl, phenyl, or substituted phenyl;

R₂, R₃, R₄ and R₅ are H or C₁ to C₇ alkyl, and R₁, R₂, R₃, R₄ and R₅ may be the same or different; and


X is C₁ to C₇, or a saturated or unsaturated C₂ carbon chain, with the proviso that if R is CH₃, then X must be CH₂, or a saturated C₂ carbon chain.

14. (Cancel)

15. (Previously presented) The method of claim 13, wherein said agonist is selected from the group consisting of




and



16. (Cancel)

- 9 -

17. (Currently amended) A method for treating obesity in a patient comprising administering to said patient an effective dose of a silent antagonist of a CB1 cannabinoid receptor wherein said silent antagonist includes a sulfonamide moiety, wherein said silent antagonist is



18-20. (Cancelled)